Meisenheim

Researchers are evaluating the efficacy, safety, and tolerability of BMS-986368 in adults with Multiple Sclerosis Spasticity. This Phase 2 randomized, double-blind, placebo-controlled study aims to assess three different doses of this oral FAAHMAGL inhibitor to better understand its impact on spasticity symptoms in participants diagnosed with MS who have experienced spasticity for at least six months. Participants will be randomly assigned to one of four groups receiving either one of three doses of BMS-986368 or a placebo. The medication is administered orally on specified days during the study period. The trial includes a treatment phase lasting six weeks, followed by safety monitoring up to 16 weeks to evaluate adverse events and treatment tolerability. During the study, participants will undergo assessments including the Total Numeric-transformed Modified Ashworth Scale for the most affected lower limb, Numeric Rating Scale for Spasticity, MS Spasticity Scale, Timed 25-Foot Walk, and Clinical Global Impression of Severity. Researchers will monitor plasma drug levels and adverse events, including suicidal ideation and withdrawal symptoms, throughout the trial. The study duration and follow-up span up to 16 weeks from treatment start.

This research aims to strengthen the resilience of hospital staff teams by evaluating the TeamTime intervention. Unlike most programs focusing on individual resilience, this study centers on team resilience, exploring factors that promote or hinder the interventions implementation and effectiveness. Participants include hospital employees, and the research is conducted by the Catholic University of Applied Sciences Mainz. The TeamTime intervention has two phases first, team leaders receive training on healthy leadership, resilience, workplace safety, psychological empowerment, and coaching techniques. After this qualification, teams engage in regular sessions involving self-reflection, stress assessment, prioritization, and collaborative problem-solving. The study includes both an intervention group receiving TeamTime and a control group with no intervention. Participants will be surveyed at three points baseline, six months, and twelve months later. Assessments include questionnaires measuring individual, team, and organizational resilience, psychological empowerment, organizational commitment, team collaboration, personality traits, willingness to change, and psychosocial workplace factors. The study tracks how these measures evolve over time to understand the impact of the intervention on team resilience.